Pharmakotherapie der chronischen Herzinsuffizienz bei Hund und Katze

• Literatur

• 1 Baggot JD. The pharmacological basis of cardiac drug selection for use in horses. Equine Vet J 1995; 19 (Suppl): 97-100.
• 2 BENCH Study Group. Benazepril in Canine Heart disease. The effect of Benazepril on survival times and clinical signs of dogs with congestive heart failure: Results ofa multi-centre, prospective, randomized, double-blinded, placebocontrolled, long-term clinical trial. J Vet Cardiol 1999; 01: 7-18.
• 3 Berger R, Ditzel P. Therapie von Herz-Kreislauferkrankungen: Der Kampf gegen die Todesursache Nummer Eins. Dtsch Apothekerzeitung 1989; 129 (05) 215ff.
• 4 Bertsche T, Schulz M. Angiotensin receptor antagonists. A clinical-pharmacologic overview. Med Monatsschr Pharm 2005; 28: 4-16.
• 5 Bohn FK. Gibt es eine optimale Therapie der chronischen Herzinsuffizienz?. Tierärztl Umsch 1996; 51: 647-54.
• 6 Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br HeartJ 1994; 71: 146-50.
• 7 CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
• 8 COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. J Vet Int Med 1995; 09: 243-52.
• 9 de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
• 10 Fox PR, Sisson D, Moise NS. Textbook of Canine and Feline Cardiology – Principles and Clinical Practice. Philadelphia: Saunders; 1999
• 11 Fuentes VL, Corcoran B, French A, Schober KE, Kleemann R, Justus C. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002; 16: 255-61.
• 12 Fujino K, Sperelakis N, Solaro RJ. Sensitization of dog and guinea pig heart myofilaments to Ca²⁺ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988; 63: 911-22.
• 13 Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-92.
• 14 Givertz M. Manipulation of the renin-angiotensin system. Circulation 2001; 104: E14-18.
• 15 Glaus T. Herzkrankheiten. In Praktikum der Hundeklinik. Suter P, Kohn B. Hrsg. Berlin: Parey; 2006: 524-65.
• 16 Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure therapy–a silver bullet?. J Am Anim Hosp Assoc 2006; 42: 90-3.
• 17 Gottlieb SS, Fisher ML, Pressel MD, Patten RD, Weinberg M, Greenberg N. Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. Am HeartJ 1993; 125: 1645-50.
• 18 Heinzl S. News in cardiology. Reports from the 19th Congress of the European Society for cardiology in Stockholm and from the 70th anniversary of the American Heart association in Orlando. Med Monatsschr Pharm 1998; 21: 40-51.
• 19 Hofmann S. Untersuchung zur Wirksamkeit und Verträglichkeit von Ramipril im Vergleich zu Captopril bei der Herzinsuffizienz des Hundes. Diss., Tierärztliche Hochschule Hannover, Fachbereich Veterinärmedizin. 1997
• 20 Hoppe UC, Erdmann E. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 2001; 90: 218-37.
• 21 Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7.
• 22 Kato K. Clinical efficacy and safety of pimobendan in treatment of heart failure – experience in Japan. Cardiology 1997; 88 (Suppl. 02) 28-36.
• 23 Kittleson MD, Kienle RD. Management of heart failure. In: Small Animal Cardiovascular Medicine. Kittleson MD, Kienle RD. eds. St. Louis: Mosby; 1998: 149-89.
• 24 Kleemann R, Le Bobinnec G, Bruyere D, Justus C, Schmidt H. Clinical efficacy of vetmedin in comparison to digoxin for the treatment of congestive heart failure in dogs. Proceedings of 14th European FECAVA SCIVAC Congress; Bologna: 1998. June 18-21 513.
• 25 Löscher W, Ungemach FR. Kreislaufwirksame Pharmaka. In: Pharmakotherapie bei Haus und Nutztieren. Löscher W, Ungemach FR, Kroker R. Hrsg. Berlin: Parey; 2006: 150-5.
• 26 Lombard CW, Jöns O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006; 42: 249-61.
• 27 Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, Dumont JM, Seed P. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-31.
• 28 MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/ XL Randomised Intervention Trial in Congestive Heart Failure. Lancet 1999; 353: 2001-7.
• 29 Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
• 30 Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C. et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
• 31 Pitt B, Chang P, Timmermans PB. Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 1995; 09: 693-700.
• 32 Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study-ELITE II. J Card Fail 1999; 05: 146-54.
• 33 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
• 34 Plumb DC. Veterinary Drug Handbook. White Bear Lake (USA): PharmaVet Publishing; 1999: 853.
• 35 Pouleur H, Gurne O, Hanet C, Balasim H, Van Mechelen H, Charlier AA. Effects of pimobendan (UD-CG 115) on the contractile function of the normal and “postischemic” canine myocardium. J Cardiovasc Pharmacol 1988; 11: 100-16.
• 36 Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet 1987; 02: 709-11.
• 37 Rush JE. Therapy of feline hypertrophic cardiomyopathy. Vet Clin North Am Small Anim Pract 1998; 28: 1459-79.
• 38 Schille JF. Untersuchungen zur Wirksamkeit, Verträglichkeit und Sicherheit des ACE-Hemmers Ramipril bei Katzen mit Kardiomyopathien und Hypertension. Diss., Freie Universität; Berlin, FachbereichVeterinärmedizin: 2001
• 39 Schölkens BA, Landgraf W. ACE inhibition and atherogenesis. Internist (Berl) 2001; 42: 1219-25.
• 40 Schütz W. Pharmakotherapie der Herzinsuffizienz. In: Allgemeine und spezielle Pharmakologie und Toxikologie. Forth W, Henschler D, Rummel W, Förstermann U, Starke K. Hrsg. München: Urban & Fischer; 2001: 449-63.
• 41 Shimoyama H, Sabbah HN, Rosman H, Kono T, Alam M, Goldstein S. Effects of long-term therapy with enalapril on severity of functional mitral regurgitation in dogs with moderate heart failure. J Am Coll Cardiol 1995; 25: 768-72.
• 42 Silver MA. Intermittent inotropes for advanced heart failure: inquiring minds want to know. Am HeartJ 1999; 138: 191-2.
• 43 Smith PJ, French AT, Van Israel N, Smith SGW, Swift ST, Lee AJ, Corcoran DM, Dukes-Mc-Ewan J. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005; 46: 121-30.
• 44 The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
• 45 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
• 46 Tilley LP. Krankheiten des Kreislaufsystems. In: Katzenkrankheiten: Klinik und Therapie. Kraft W, Dürr U. Hrsg. Hannover: Schaper; 1991: 215-44.
• 47 Tilley LP, Skrodzki M, Trautvetter E. Krankheiten des Kreislaufsystems. In: Katzen Krankheiten, 5. Aufl. Kraft W, Dürr UM, Hartmann K. Hrsg. Hannover: Schaper; 2003: 593-635.
• 48 Tobias R, Kersten U. Zur Therapie der Herzinsuffizienz des Hundes mit ACE-Hemmern. Kleintierprax 1992; 37: 19-22.
• 49 Ungemach FR. Behandlung von Hypertonie und Hypotonie. In: Blutdruck auf den Punkt gebracht. Egner B. Hrsg. Berlin: Parey; 2002: 93-124.
• 50 Ungemach FR. Diuretika. In: Pharmakotherapie bei Haus und Nutztieren. Löscher W, Ungemach FR, Kroker R. Hrsg. Berlin: Parey; 2006: 179-88.
• 51 Ungemach FR. Herzwirksame Pharmaka. In: Pharmakotherapie bei Haus und Nutztieren. Löscher W, Ungemach FR, Kroker R. Hrsg. Berlin: Parey; 2006: 131-49.
• 52 Unger T, Rangoonwala B, Rosenthal J. ACE inhibitor or AT1 antagonist. Is there a differential therapy? MMW Fortschr Med 2002; 144: 36-8.
• 53 Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J 1995; 16 (Suppl N): 79-85.
• 54 van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989; 14 (Suppl. 02) S1-6.
• 55 Wright JM. Choosing afirst-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. CMAJ 2000; 163 (02) 188-92.